• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关节炎治疗期间疾病和胃肠道副作用的直接医疗费用。

Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.

作者信息

Bloom B S

机构信息

University of Pennsylvania, Philadelphia 19104-6020.

出版信息

Am J Med. 1988 Feb 22;84(2A):20-4. doi: 10.1016/0002-9343(88)90250-1.

DOI:10.1016/0002-9343(88)90250-1
PMID:3348239
Abstract

We conducted a study to determine the costs of caring for patients with arthritis. Data were obtained from the Medicaid Management Information System (MMIS) of Washington, DC. A retrospective analysis was undertaken of all direct medical costs related to individual Medicaid recipients who obtained treatment for arthritis. First, all data were adjusted for patient compliance with nonsteroidal anti-inflammatory drugs (NSAIDs). Second, we determined the actual expenditure of treating arthritis. Last, the medical costs of treating adverse gastrointestinal side effects were examined. There was a linear relationship between compliance and pharmaceutical dose schedule per diem. Treatment costs per quarter were $145; 54 percent of the cost was for NSAIDs with the remainder equally divided between physician and hospital costs. Approximately 25 percent of the population experienced NSAID-related gastrointestinal side effects that required further medical care. The per-quarter mean cost of treating these adverse gastrointestinal drug reactions was $66 per person, which added nearly 46 percent to the per-quarter mean cost of treatment. The total cost of treating patients with arthritis therefore averaged $211 per quarter. Nearly one third of overall cost went to provide medical care to the 25 percent of the population who experienced adverse reactions, and slightly more than two thirds went towards treating the disease itself. Overall costs of treating adverse drug reactions were accounted for by pharmaceuticals (about 42 percent), usually the histamine (H2)-receptor antagonist cimetidine, rare but expensive inpatient hospital care (about 38 percent) and physician visits (about 20 percent).

摘要

我们开展了一项研究以确定关节炎患者的护理成本。数据取自华盛顿特区的医疗补助管理信息系统(MMIS)。对所有接受关节炎治疗的医疗补助受助人的所有直接医疗费用进行了回顾性分析。首先,对所有数据按照患者对非甾体抗炎药(NSAIDs)的依从性进行了调整。其次,我们确定了治疗关节炎的实际支出。最后,对治疗胃肠道不良副作用的医疗费用进行了审查。依从性与每日药物剂量安排之间存在线性关系。每季度的治疗费用为145美元;其中54%用于非甾体抗炎药,其余费用在医生和医院费用之间平均分配。约25%的人群出现了与非甾体抗炎药相关的胃肠道副作用,需要进一步治疗。治疗这些胃肠道药物不良反应的每季度人均平均费用为66美元,这使每季度平均治疗费用增加了近46%。因此,关节炎患者的每季度治疗总成本平均为211美元。近三分之一的总成本用于为出现不良反应的25%的人群提供医疗护理,略多于三分之二用于治疗疾病本身。药物(约42%)是治疗药物不良反应总成本的主要构成部分,通常是组胺(H2)受体拮抗剂西咪替丁,罕见但昂贵的住院治疗(约38%)和医生诊疗(约20%)也占了一定比例。

相似文献

1
Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.关节炎治疗期间疾病和胃肠道副作用的直接医疗费用。
Am J Med. 1988 Feb 22;84(2A):20-4. doi: 10.1016/0002-9343(88)90250-1.
2
Cost of treating arthritis and NSAID-related gastrointestinal side-effects.治疗关节炎及非甾体抗炎药相关胃肠道副作用的费用。
Aliment Pharmacol Ther. 1988;2 Suppl 1:131-8. doi: 10.1111/j.1365-2036.1988.tb00772.x.
3
Final report on the cost of treating arthritic disease: comparison between salicylates and nonsalicylate nonsteroidal anti-inflammatory drugs.
Semin Arthritis Rheum. 1985 Feb;14(3 Suppl 1):20-4. doi: 10.1016/0049-0172(85)90056-3.
4
Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.
J Gen Intern Med. 1996 Aug;11(8):461-9. doi: 10.1007/BF02599040.
5
Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.老年患者中与非甾体抗炎药相关的胃肠道不良事件的成本。
Br J Clin Pharmacol. 2001 Aug;52(2):185-92. doi: 10.1046/j.1365-2125.2001.00348.x.
6
The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy.
Rheumatology (Oxford). 2002 Apr;41 Supp 1:7-15; discussion 35-42. doi: 10.1093/rheumatology/41.suppl_1.7.
7
Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.慢性 NSAID 使用者的胃保护策略:比较单一片剂与单一成分的成本效益分析。
Value Health. 2013 Jul-Aug;16(5):769-77. doi: 10.1016/j.jval.2013.05.002. Epub 2013 Jul 11.
8
The iatrogenic costs of NSAID therapy: a population study.非甾体抗炎药治疗的医源性成本:一项人群研究。
Arthritis Rheum. 2002 Apr 15;47(2):132-40. doi: 10.1002/art.10268.
9
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.将非甾体抗炎药的并发症降至最低:不同风险群体中竞争策略的成本效益
Arthritis Rheum. 2005 Apr 15;53(2):185-97. doi: 10.1002/art.21065.
10
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.依托考昔与非选择性非甾体抗炎药治疗英国骨关节炎和类风湿关节炎患者的经济学评价
Pharmacoeconomics. 2004;22(10):643-60. doi: 10.2165/00019053-200422100-00003.

引用本文的文献

1
Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis.载有泼尼松龙和甲氨蝶呤的叶酸偶联双层脂质体用于靶向类风湿关节炎。
Pharm Res. 2019 Jun 19;36(8):123. doi: 10.1007/s11095-019-2653-0.
2
Analyses of the genetic diversity and protein expression variation of the acyl: CoA medium-chain ligases, ACSM2A and ACSM2B.酰基辅酶 A:中链连接酶 ACSM2A 和 ACSM2B 的遗传多样性和蛋白表达变化分析。
Mol Genet Genomics. 2018 Oct;293(5):1279-1292. doi: 10.1007/s00438-018-1460-3. Epub 2018 Jun 14.
3
Topical Administration of Ibuprofen for Injured Athletes: Considerations, Formulations, and Comparison to Oral Delivery.
布洛芬对受伤运动员的局部给药:注意事项、制剂及与口服给药的比较。
Sports Med Open. 2017 Oct 5;3(1):36. doi: 10.1186/s40798-017-0103-2.
4
Ultrasound-guided interventional procedures around the shoulder.肩部周围的超声引导介入操作
Br J Radiol. 2016;89(1057):20150372. doi: 10.1259/bjr.20150372. Epub 2015 Sep 23.
5
Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.依托考昔与塞来昔布及非选择性非甾体抗炎药治疗挪威强直性脊柱炎的成本效益评估
Int J Rheumatol. 2011;2011:160326. doi: 10.1155/2011/160326. Epub 2011 Jun 24.
6
Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends.超声介导的经皮药物传递:机制、范围和新兴趋势。
J Control Release. 2011 Jun 30;152(3):330-48. doi: 10.1016/j.jconrel.2011.01.006. Epub 2011 Jan 14.
7
Ultrasound-guided viscosupplementation of subacromial space in elderly patients with cuff tear arthropathy using a high weight hyaluronic acid: prospective open-label non-randomized trial.超声引导下肩袖撕裂性关节病老年患者肩峰下间隙高浓度透明质酸钠注射治疗:前瞻性、开放标签、非随机临床试验
Eur Radiol. 2011 Jan;21(1):182-7. doi: 10.1007/s00330-010-1894-4. Epub 2010 Jul 25.
8
Current state of therapy for pain and inflammation.疼痛与炎症的当前治疗状况。
Arthritis Res Ther. 2005;7 Suppl 4(Suppl 4):S1-6. doi: 10.1186/ar1792. Epub 2005 Sep 15.
9
International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.类风湿关节炎资源利用和治疗成本的国际差异:一项系统文献综述
Pharmacoeconomics. 2005;23(3):243-57. doi: 10.2165/00019053-200523030-00005.
10
Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: protocol of a randomized controlled trial [ISRCTN43532635].鼓励医生合理开具非甾体抗炎治疗药物:一项随机对照试验的方案 [国际标准随机对照试验编号:ISRCTN43532635]
BMC Health Serv Res. 2004 Aug 24;4(1):21. doi: 10.1186/1472-6963-4-21.